264 related articles for article (PubMed ID: 8707338)
1. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H.
Brett S; Baxter G; Cooper H; Johnston JM; Tite J; Rapson N
Immunology; 1996 May; 88(1):13-9. PubMed ID: 8707338
[TBL] [Abstract][Full Text] [Related]
2. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes.
Rowan WC; Hale G; Tite JP; Brett SJ
Int Immunol; 1995 Jan; 7(1):69-77. PubMed ID: 7718516
[TBL] [Abstract][Full Text] [Related]
3. Emergence of CD52-, glycosylphosphatidylinositol-anchor-deficient lymphocytes in rheumatoid arthritis patients following Campath-1H treatment.
Brett SJ; Baxter G; Cooper H; Rowan W; Regan T; Tite J; Rapson N
Int Immunol; 1996 Mar; 8(3):325-34. PubMed ID: 8671618
[TBL] [Abstract][Full Text] [Related]
4. Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52).
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Eur J Haematol; 1997 Jan; 58(1):5-13. PubMed ID: 9020367
[TBL] [Abstract][Full Text] [Related]
5. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
[TBL] [Abstract][Full Text] [Related]
6. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
[TBL] [Abstract][Full Text] [Related]
7. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Rowan W; Tite J; Topley P; Brett SJ
Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
[TBL] [Abstract][Full Text] [Related]
8. Emergence of oligoclonal T cell populations following therapeutic T cell depletion in rheumatoid arthritis.
Jendro MC; Ganten T; Matteson EL; Weyand CM; Goronzy JJ
Arthritis Rheum; 1995 Sep; 38(9):1242-51. PubMed ID: 7575719
[TBL] [Abstract][Full Text] [Related]
9. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
10. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
11. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
Shah A; Lowenstein H; Chant A; Khan A
Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
[TBL] [Abstract][Full Text] [Related]
12. Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
Taylor VC; Sims M; Brett S; Field MC
Biochem J; 1997 Mar; 322 ( Pt 3)(Pt 3):919-25. PubMed ID: 9148769
[TBL] [Abstract][Full Text] [Related]
13. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.
Watanabe T; Masuyama J; Sohma Y; Inazawa H; Horie K; Kojima K; Uemura Y; Aoki Y; Kaga S; Minota S; Tanaka T; Yamaguchi Y; Kobayashi T; Serizawa I
Clin Immunol; 2006 Sep; 120(3):247-59. PubMed ID: 16797237
[TBL] [Abstract][Full Text] [Related]
14. Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function.
Fishwild DM; Strand V
J Rheumatol; 1994 Apr; 21(4):596-604. PubMed ID: 7518519
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
16. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
17. [The interrelation of the expression of HLA class I and II proteins and of the costimulatory proteins CD11a/CD18 and CD16 with the lytic activity of resting and activated natural killer lymphocytes].
Musatov MI; Petrova ED; Konenkov VI
Tsitologiia; 1997; 39(7):617-28. PubMed ID: 9490502
[TBL] [Abstract][Full Text] [Related]
18. CAMPATH-1H in inflammatory arthritis.
Watts RA; Isaacs JD; Hale G; Hazleman BL; Waldmann H
Clin Exp Rheumatol; 1993; 11 Suppl 8():S165-7. PubMed ID: 8324942
[TBL] [Abstract][Full Text] [Related]
19. Synovial tissue response to treatment with Campath-1H.
Ruderman EM; Weinblatt ME; Thurmond LM; Pinkus GS; Gravallese EM
Arthritis Rheum; 1995 Feb; 38(2):254-8. PubMed ID: 7531440
[TBL] [Abstract][Full Text] [Related]
20. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis.
Hudnall SD; Patel J; Schwab H; Martinez J
Cytometry B Clin Cytom; 2003 Sep; 55(1):22-8. PubMed ID: 12949956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
